Clinical trials: HHT, open to volunteers
Hereditary Haemorrhagic Telangiectasia
Immunological Effects of Iron Supplementation in HHT Disease
Hereditary haemorrhagic telangiectasia (HHT), is a rare genetic vascular disorder with autosomal dominant inheritance. Its prevalence is estimated at approximately 1 in 6,000 individuals in France.
- Trial name
- Fer&RO (NCT07111598)
- Testing
- Blood test at D0, Blood test at D+3 months
- Where
- France
- Volunteers
- 155 people
- Sponsor
- Hospices Civils de Lyon
Acute Myeloid Leukemia (AML), Elderly Patients (60-75 Years)
VAH vs VA in Newly Diagnosed Elderly AML
This is a multicenter, open-label, randomized, controlled phase III clinical trial designed to evaluate the efficacy and safety of the combination of Venetoclax, Azacitidine, and Homoharringtonine (VAH) compared to Venetoclax and…
- Trial name
- NCT07469046
- Testing
- Venetoclax, Azacitidine, Homoharringtonine
- Where
- China
- Volunteers
- 308 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Acute Myeloid Leukemia
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
This study is a single-center, single-arm, prospective phase II clinical trial evaluating the efficacy and safety of the VAH (Venetoclax and Azacitidine combined with Homoharringtonine) regimen, followed by allo-HSCT for…
- Trial name
- NCT06483906
- Testing
- Venetoclax, Azacitidine and Homoharringtonine
- Where
- China
- Volunteers
- 56 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Prostate CA
Clinical Study on Neoadjuvant Therapy of Homoharringtonine Combined With Androgen Deprivation for Prostate Cancer
The high incidence of prostate cancer is one of the important diseases that threaten the health of old men in our country. Although androgen deprivation therapy is an important treatment option for prostate cancer, although…
- Trial name
- NCT06834321
- Testing
- Homoharringtonine combined with androgen deprivation therapy, radical prostatectomy
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- baotai Liang
Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Pediatric T-cell ALL Protocol
This is a prospective, multicenter study conducted within the Chinese Children's Cancer Group (CCCG). The study aims to evaluate whether the addition of three novel agents, dasatinib, venetoclax and homoharringtonine, can improve…
- Conditions
- Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- Trial name
- CCCG-TALL-2025 (NCT06855810)
- Testing
- Venetoclax, Dasatinib, homoharringtonine
- Where
- 27 sites in China, Hong Kong
- Volunteers
- 610 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Rare Diseases, Amyloidosis
Institutional Registry of Rare Diseases
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).
- Conditions
- Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis
- Trial name
- NCT06573723
- Where
- Argentina
- Volunteers
- 380 people
- Sponsor
- Hospital Italiano de Buenos Aires
Bevacizimab, HHT
Bevacizumab in the Treatment of HHT
Clinical Study Abstract (Ethics Application) Hereditary hemorrhagic telangiectasia (HHT) is a rare autosomal dominant vascular disorder characterized by recurrent intractable epistaxis and multi-organ arteriovenous malformations.
- Trial name
- NCT07828015
- Testing
- Bevacizumab, nasal electrocoagulation., Thalidomide (50mg)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Hereditary Hemorrhagic Telangiectasia
Quality of Life in Patients With Hemorrhagic Telangiectasia
Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler's disease, is a genetic disorder that leads to abnormal blood vessel formations.
- Trial name
- NCT06261333
- Testing
- Questionnaires
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- University Hospital, Essen
Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
This study aims to evaluate the safety and efficacy of homoharringtonine combined with venetoclax and azacitidine regimen (HVA) in newly diagnosed MPAL patients, providing a basis for the use of the HVA regimen in the treatment…
- Trial name
- HVA-MPAL (NCT07517510)
- Testing
- HVA
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Guangdong Second Provincial General Hospital
Acute Myeloid Leukemia (AML)
Efficacy and Safety of Lisafotoclax Plus Decitabine and Homoharringtonine in Venetoclax/Azacitidine Pretreated AML Patients
This is a multi-center, prospective, single-arm, phase 2 clinical study conducted in China to evaluate the efficacy and safety of Lisafotoclax combined with Decitabine and Homoharringtonine in patients with acute myeloid leukemia…
- Trial name
- NCT07505160
- Testing
- Lisafotoclax, Decitabine, Homoharringtonine
- Where
- China
- Volunteers
- 35 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Myeloid Leukemia
Clinical Study Protocol for the Treatment of ND-AML and RR-AML With KMT2A Gene Abnormalities Using VHEA.
This study is a clinical trial aimed at evaluating the efficacy and safety of the VHEA（Venetoclax with Homoharringtonine，Etoposide，Cytarabine）regimen in the treatment of newly diagnosed and relapsed/refractory acute myeloid…
- Trial name
- NCT06328179
- Testing
- Venetoclax 100 mg d1，200 mg d2，400 mg d3-14；
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Huai'an First People's Hospital
Telangiectasia, Hereditary Hemorrhagic
Efficacy of Nintedanib for Treatment of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT) Patients
Patients affected by hereditary hemorrhagic telangiectasia (HHT) very often suffer from recurrent nosebleeds called epistaxis. There is no treatment currently available to reduce the frequency or severity of epistaxis.
- Trial name
- EPISTOP (NCT04976036)
- Testing
- Nintedanib
- Where
- 3 sites in France, Switzerland
- Volunteers
- 48 people
- Sponsor
- Dr. Romain Lazor
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
This is a 2-part study evaluating ATV-1601 in participants with moderate to severe HHT. Part 1 is a randomized, double-blind, placebo-controlled study evaluating 3 dosing regimens of ATV-1601.
- Trial name
- NCT07601425
- Testing
- ATV-1601
- Where
- 10 sites in United States, Argentina
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Atavistik Bio, Inc
Acute Myeloid Leukemia (AML)
Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)
This study is a single-arm, prospective, multi-center exploratory clinical trial. A total of 61 patients with newly diagnosed acute myeloid leukemia (AML) who are not suitable for intensive chemotherapy will be enrolled.
- Trial name
- VHAG (NCT07507825)
- Testing
- Intervention for Venetoclax, Intervention for Homoharringtonine, Intervention for Azacitidine
- Where
- China
- Volunteers
- 61 people
- Sponsor
- First People's Hospital of Hangzhou
Prostate Cancer
Homoharringtonine Plus Androgen Deprivation Therapy in the Neoadjuvant Treatment of Prostate Cancer: A Single-Arm Clinical Study
The project aims to verify the therapeutic effect of neoadjuvant homoharringtonine combined with androgen deprivation therapy in patients with localized high-risk/very high-risk, regional lymph node-metastatic, or metastatic…
- Trial name
- NCT07163910
- Testing
- homoharringtonine, Radical prostatectomy
- Where
- China
- Volunteers
- 93 people
- Sponsor
- baotai Liang
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations
Comprehensive HHT Outcomes Registry of the United States (CHORUS)
The Comprehensive HHT Outcomes Registry of the United States (CHORUS) is an observational registry of patients diagnosed with Hereditary Hemorrhagic Telangiectasia (HHT).
- Conditions
- Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis
- Trial name
- CHORUS (NCT06259292)
- Where
- 16 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Cure HHT
Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension
Efficacy and Tolerance of Treatment With Bevacizumab for Severe Liver Involvement With High Cardiac Output in Hereditary Hemorrhagic Telangiectasia Within the French Hereditary Hemorrhagic Telangiectasia Network
High cardiac output secondary to hepatic arteriovenous malformations may be isolated or associated with left heart failure with post-capillary pulmonary hypertension.
- Conditions
- Hereditary Hemorrhagic Telangiectasia (HHT), Pulmonary Hypertension, Bevacizumab
- Trial name
- BevaHHearT (NCT07445347)
- Testing
- Bevacizumab
- Where
- France
- Volunteers
- 111 people
- Sponsor
- Poitiers University Hospital
Acute Myeloid Leukemia
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
This study aims to evaluate the efficacy and safety of venetoclax combined with homoharringtonine and cytarabine in the treatment of newly diagnosed acute myeloid leukemia.
- Trial name
- VHA (NCT05805098)
- Testing
- Venetoclax, Homoharringtonine, Cytarabine
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Haemorrhagic Hereditary Telangiectasia
Institutional Registry of Haemorrhagic Hereditary Telangiectasia
The purpose of this study is to create an institutional and population-based registry of Haemorrhagic Hereditary Telangiectasia with a prospective survey based on epidemiological data, risk factors, diagnosis, prognosis…
- Trial name
- NCT01761981
- Where
- Argentina
- Volunteers
- 590 people
- Sponsor
- Hospital Italiano de Buenos Aires
Hereditary Hemorrhagic Telangiectasia (HHT)
Phase 1b Study of TX002100 in Participants With Hematologic Support-Dependent Hereditary Hemorrhagic Telangiectasia (HHT)
The primary purpose of this study is to assess the safety and tolerability of TX002100 in participants with hereditary hemorrhagic telangiectasia (HHT).
- Trial name
- NCT07863609
- Testing
- TX002100
- Volunteers
- 20 people
- Sponsor
- Tectonic Operating Company, Inc.